BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Big Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2276.64 only $796.82

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
US Tech 100
20,266.40
0.33%
Dow Jones
44,296.51
0.97%
Brent Oil
74.65
0.00%
Bitcoin
98,000.00
0.22%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Esperion Therapeutics Inc (ESPR) Quote

Esperion Therapeutics Inc

Esperion Therapeutics Inc (ESPR)

NASDAQ
2.52
0.05
(2.02%)
Closed November 23 4:00PM
Delayed by 15 minutes
2.48
-0.04
(-1.59%)
After Hours: 7:21PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.48
Bid
2.48
Ask
2.50
Volume
3,157,468
2.45 Day's Range 2.54
1.1601 52 Week Range 3.40
Market Cap
488.647M
Previous Close
2.47
Open
2.48
Last Trade
200
@
2.48
(formt)
Last Trade Time
Financial Volume
$ 7,871,405
VWAP
2.4929
Average Volume (3m)
3,789,360
Shares Outstanding
197,035,171
Dividend Yield
-
PE Ratio
-2.38
Earnings Per Share (EPS)
-1.06
Revenue
116.33M
Net Profit
-209.25M

About Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi... Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.esperion.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Esperion Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ESPR. The last closing price for Esperion Therapeutics was $2.47. Over the last year, Esperion Therapeutics shares have traded in a share price range of $ 1.1601 to $ 3.40.

Esperion Therapeutics currently has 197,035,171 shares outstanding. The market capitalization of Esperion Therapeutics is $486.68 million. Esperion Therapeutics has a price to earnings ratio (PE ratio) of -2.38.

Ask ADVFN Intelligence (AI)

ESPR Latest News

More News

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare...

November 21 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

November 20 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

November 19 2024
Edgar (US Regulatory)

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024...

November 18 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs...

November 08 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 07 2024
Edgar (US Regulatory)

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

U.S. index futures rose in Thursday’s pre-market session following Donald Trump’s victory, which sent the Dow Jones up over 1,500 points yesterday. Investors are watching for the Federal...

November 07 2024
IH Market News

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and...

November 07 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.36517.25768321512.1152.532.0251004762.2812707CS
40.4119.8067632852.072.61.9351819132.23640985CS
120.7140.11299435031.772.61.5837893602.03625945CS
260.041.63934426232.443.121.5853962722.2293299CS
521.27104.9586776861.213.41.160160798362.29109606CS
156-5-66.84491978617.4810.020.735902452.83459492CS
260-44.82-94.756871035947.379.9890.724331986.28000533CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PDYNPalladyne AI Corporation
$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
$ 8.26
(89.02%)
2.03M
XCURExicure Inc
$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
$ 0.0201
(-0.50%)
415.87M
NVDANVIDIA Corporation
$ 141.95
(-3.22%)
229.93M
SMCISuper Micro Computer Inc
$ 33.15
(11.62%)
155.43M
VRPXVirpax Pharmaceuticals Inc
$ 0.5501
(-6.72%)
154.17M
SOUNSoundHound AI Inc
$ 8.24
(18.05%)
103.6M

ESPR Discussion

View Posts
FACT-MASTER FACT-MASTER 1 day ago
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ESPR

Next few days will determine if this is truly a trend reversal, imo. ( referring to reversing the up - smack down trend of 2024).

ESPR should hire for investor relations djohnson on st, imo.
👍️0
Gregg4 Gregg4 3 days ago
All looks good
👍️0
FACT-MASTER FACT-MASTER 3 days ago
Accumulation in progress, imo.

Trading here has taken a turn to the positive, imo, ask walls methodically being taken out.

Hope i don't get side smacked for stating that analysis.
👍 1
FACT-MASTER FACT-MASTER 4 days ago
Sounds like today's Jefferies conference was a bit more optimistic.

I'm not a member on st but often read that board, many good posters there.

https://www.thelion.com/bin/aio_msg.cgi?cmd=search&symbol=espr
👍️0
nsomniyak nsomniyak 4 days ago
Agreed.
👍️0
FACT-MASTER FACT-MASTER 4 days ago
Nice move today with good volume!

Looks like bidding was strong today, that's weird,,,, for ESPR.
👍 1
FACT-MASTER FACT-MASTER 4 days ago
Thanks for that information, however that being the case, management failed to use the opportunity to bridge some trust with the investing community by re-confirming a commitment to building shareholder value / working in the best interests of shareholders / pledging to cease share based executive compensation until the company reaches profitability / outline a plan to profitability / detail expense restraint / and outlining a plan to profitability.

I concur that 2024 has been a pivotal year of accomplishment, however the marketplace appears to be skeptical of ESPR mgmt. The current share price and market cap suggests a loss of confidence in ESPR mgmt., imo.
👍️0
Gregg4 Gregg4 4 days ago
Yup someone is buying trying to keep under wraps
👍️0
nsomniyak nsomniyak 5 days ago
The interview was sponsored by Esperion. That means the interviewer was given a predetermined script written by Esperion, he was not free to ask "top of mind" questions from a shareholder's point of view.

There were no questions about stock performance because Esperion did not want to answer any such questions.
👍️0
FACT-MASTER FACT-MASTER 5 days ago
ESPR: On deck for November 19/24

Jefferies London Healthcare Conference

https://www.esperion.com/events/event-details/jefferies-london-healthcare-conference-3

Will it be a re-hash of the poster presentations this past weekend or does Sheldon have something new to lift the spirits of long term shareholders, we will see tomorrow.

Interesting late day trading the last couple of sessions.
👍 1
Gregg4 Gregg4 5 days ago
I agree never hard questions 
👍️0
FACT-MASTER FACT-MASTER 5 days ago
https://www.fiercehealthcare.com/sponsored/2024-pivotal-year-fight-against-cardiovascular-disease

I'm always surprised that the interviewer never asks the respondant about the share price performance. If it been such a pivotal year of accomplishments, why has the stock lost approx. 50% since January 1/24?? Sheldon, can you comment on that and please expand on where you think the market cap should be and/or what exactly is the problem with ESPR stock performance?
👍 1
FACT-MASTER FACT-MASTER 5 days ago
ESPR: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

https://finance.yahoo.com/news/esperion-highlights-exploratory-data-clear-153000058.html


Sellers just can't sell enough, level II ask keeps loading. Level II = hopeless for ESPR, imo.
👍 1
FACT-MASTER FACT-MASTER 7 days ago
Esperion Corporate presentation November 2024

https://www.esperion.com/static-files/c900cfb6-ec24-45cf-81a5-ee14d1836a53

Looks like a NDA in Canada during November (slide 11) - no big deal, imo.
👍 1
FACT-MASTER FACT-MASTER 2 weeks ago
The Vanguard Group reported 10,816,762 shares held as of June 30/24.

https://www.nasdaq.com/market-activity/stocks/espr/institutional-holdings

The Vanguard Group reported 13,043,077 shares held as of September 30/24

https://archive.fast-edgar.com/20241104/AB22M222Z222VJD222222ZO2LQ2ST322B262/UnitedStates_13G__EsperionTh.txt

Increase of 2,226,315 shares in the 3rd quarter
👍 1
Gregg4 Gregg4 2 weeks ago
Hope so been long almost 4 years
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
It seems something big is in the works.

Haven't seen Level II act the way it did today, ask in the low 2.50-2.53 were getting repeatedly annihilated.

Could be a major partnering, or a buyout in the works, imo.
👍️0
Gregg4 Gregg4 2 weeks ago
Yes one trade almost a million shares 
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
AH volume on fire!

https://www.nasdaq.com/market-activity/stocks/espr/after-hours
👍️0
Gregg4 Gregg4 2 weeks ago
Yup
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
Strong to the close.

Looking good!, imo.
👍 1
FACT-MASTER FACT-MASTER 2 weeks ago
WOW! nice move north!

Level II bid looking pretty strong.

Pleasantly surprised here this morning!
👍 1
FACT-MASTER FACT-MASTER 2 weeks ago
Nascar promotional collaboration 2024 has failed, imo

https://www.esperion.com/news-releases/news-release-details/rfk-esperion-therapeutics-announce-2024-promotional-schedule

It's time for ESPR mgmt. to get serious and employ competent, dedicated sales reps who know how to get the job done!

https://www.youtube.com/shorts/zlkURHOXkKs
👍 1
FACT-MASTER FACT-MASTER 2 weeks ago
ESPR: Form 10-Q

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024046307/espr-20240930.htm
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
ESPR: No funds available to redeem convert.notes, imo.

Cash and cash equivalents $ 144,717,000

and losing 30$ million per quarter - does not look good, imo
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
ESPR: For what??? Losing money?? ( in bold below)

2024 Financial Outlook

The Company reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.

and here under SG&A

The increase is primarily related to the ramp up of our sales force associated with our commercial launch in addition to bonus payments and promotional costs.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

ESPR mgmt. spending appears to be out of control. imo.

Only positive today is that ESPR is not sub$2, imo.
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
ESPR: Official earnings SEC filing

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

Problem areas, imo:

Selling, general and administrative 39,975,000
Interest expense (15,082,000)

Whatever they are spending money on in the "Selling, general and administrative" like NasCar and sales reps - it's not working.

Overall prognosis is poor, and financials are weak.

No news on the converts in the near term will mean no profitability anytime soon, imo.
👍 1
FACT-MASTER FACT-MASTER 2 weeks ago
ESPR:
👍️0
FACT-MASTER FACT-MASTER 2 weeks ago
$2.25 rejected.

Perpetual wall on the ask at $2.25.

What are we anticipating for tomorrow's earnings call?

It seems positive imo, that the earnings release is prior to the open, as opposed to releasing the earnings after the close.
👍 1
FACT-MASTER FACT-MASTER 4 weeks ago
scriptstrend on ST shares some good points.

https://stocktwits.com/scriptstrend2024/message/590178774

ESPR mgmt. needs to pay attention:

https://www.youtube.com/shorts/aZctsTD1iJY
👍 1
Gregg4 Gregg4 4 weeks ago
Guess we will see 11/7
👍️0
FACT-MASTER FACT-MASTER 4 weeks ago
I'm not expecting anything spectacular from the 3rd quarter results.

ESPR management team has failed long term investors by squandering shareholder value.
From what i have seen here, their expenditures are not translating into sales.

Great clinical trial results / great product / stock price barely holding a measly $2 dollars says ESPR management has failed - big time, imo.
👍️0
Gregg4 Gregg4 1 month ago
Just dreaming probably nothing but I'm hoping start of a long march upward 
👍️0
FACT-MASTER FACT-MASTER 1 month ago
Is what?
👍️0
Gregg4 Gregg4 1 month ago
This is it
👍️0
FACT-MASTER FACT-MASTER 1 month ago
Esperion to Report Third Quarter 2024 Financial Results on November 7

https://finance.yahoo.com/news/esperion-report-third-quarter-2024-120000845.html
👍️0
FACT-MASTER FACT-MASTER 1 month ago
https://finance.yahoo.com/news/millennium-management-llcs-strategic-reduction-230255195.html

As i mentioned previously, there could be something that is repulsive regarding ESPR mgmt.
A fund just doesn't dump that many shares at a bargain price for no reason. Something made then lose interest big time, and the only thing i can think of is ESPR mgmt.

Did this fund take a huge loss upon selling that huge portion of ESPR stock?

Not good, imo.
👍️0
Gregg4 Gregg4 2 months ago
I agree
👍️0
FACT-MASTER FACT-MASTER 2 months ago
I think it would be logical, imo, if ESPR was going to make a move to redeem the convertible notes, to do so on the issue/maturity anniversary date - Nov.15.

If they were to redeem them this year that would be one year prior to the final maturity of November 15/25.

That makes sense, imo, so if they are going to move on the convertible notes this year, we should be hearing about details between now and say November 5/10ish.
👍️0
glenn1919 glenn1919 2 months ago
ESPR.........................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
Gregg4 Gregg4 2 months ago
Love it
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Another great day here at ESPR!

AH $2.18
👍️0
Gregg4 Gregg4 2 months ago
Yes thanks still need to make up ground
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Comprende amigo.

I think your on the right track now, i do the same, only buy stock, stay out of options / etf's etc.

Your off to a great start today!
👍️0
Gregg4 Gregg4 2 months ago
No I lost massive cash in options past few months August and September I sold all my shares and went to options last fall when we hit .70 did very we’ll be played the game too long got burned three years makes u impatient so I started over with stock only
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Congrats on that! looks like you picked a good day to get in.

Did you previously sell out, and now just bought back in?

I thought you were a dedicated bagholder like the rest of us, (lol)
👍️0
Gregg4 Gregg4 2 months ago
Back in all stock 57,620 $1.65
👍️0
Gregg4 Gregg4 2 months ago
I get it too if company so great why is it at $1.65 still
👍️0
FACT-MASTER FACT-MASTER 2 months ago
I must say, i like the conviction you have about ESPR, along with the other guys on st - i see some of those guys are still buying too.

If i didn't have any shares, i would be buying at this level too, however i'v lost some confidence in mgmt and just in a holding pattern for now.

I'm hoping for news on redemption of the convertible notes. That is the remaining obstacle, imo, before this story elevates to a higher level.

All the best with your purchases tomorrow.
👍️0
Gregg4 Gregg4 2 months ago
I’m buying this tomorrow both fists 60k shares
👍️0

Your Recent History

NASDAQ
ESPR
Esperion Therapeutics
NASDAQ
EEI
Ecology and Environment
NASDAQ
ENFC
Entegra Financial
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50